drugset / Trial / NCT03100955
A Study of Standard Treatment +/- Apatinib in Extensive Stage Small Cell Lung Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
To establish the progression free survival in patients with extensive stage small cell lung cancer treated with cisplatin and etoposide plus or not apatinib
Timeline
- Start
- 2017-03-01
- Primary completion
- 2019-02-01
- Completion
- 2019-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rivoceranib | Small molecule | 500 mg | Oral |
| Comparator | Cisplatin | Other / unclassified | 75 mg/m2 | Intravenous |
| Comparator | Etoposide | Small molecule | 120 mg/m2 | Intravenous |
Indications
No indication recorded.